Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases†
Article first published online: 6 MAR 2013
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 58, Issue 1, pages 409–421, July 2013
How to Cite
Masyuk, T. V., Radtke, B. N., Stroope, A. J., Banales, J. M., Gradilone, S. A., Huang, B., Masyuk, A. I., Hogan, M. C., Torres, V. E. and LaRusso, N. F. (2013), Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology, 58: 409–421. doi: 10.1002/hep.26140
Conflict of interest: Partial financial support for this study was provided by Novartis USA (i.e., animal housing, cost of chemicals and supplies). Novartis was permitted to review the data before the article was written but the final decision on content and result interpretation was exclusively retained by the authors.
- Issue published online: 24 JUN 2013
- Article first published online: 6 MAR 2013
- Accepted manuscript online: 21 NOV 2012 03:00PM EST
- Manuscript Accepted: 6 NOV 2012
- Manuscript Received: 4 MAY 2012
- NIH. Grant Numbers: DK24031, DK44863, EB000305, CA112281, P30DK084567
- NIDDK. Grant Number: P30DK090728
- National Disease Research Interchange (NDRI)
- Novartis USA
In polycystic liver (PLD) and kidney (PKD) diseases, increased cyclic adenosine monophosphate (cAMP) levels trigger hepatorenal cystogenesis. A reduction of the elevated cAMP by targeting somatostatin receptors (SSTRs) with octreotide (OCT; a somatostatin analog that preferentially binds to SSTR2) inhibits cyst growth. Here we compare the effects of OCT to pasireotide (PAS; a more potent somatostatin analog with broader receptor specificity) on: (1) cAMP levels, cell cycle, proliferation, and cyst expansion in vitro using cholangiocytes derived from control and PCK rats (a model of autosomal recessive PKD [ARPKD]), healthy human beings, and patients with autosomal dominant PKD (ADPKD); and (2) hepatorenal cystogenesis in vivo in PCK rats and Pkd2WS25/- mice (a model of ADPKD). Expression of SSTRs was assessed in control and cystic cholangiocytes of rodents and human beings. Concentrations of insulin-like growth factor 1 (IGF1) and vascular endothelial growth factor (VEGF) (both involved in indirect action of somatostatin analogs), and expression and localization of SSTRs after treatment were evaluated. We found that PAS was more potent (by 30%-45%) than OCT in reducing cAMP and cell proliferation, affecting cell cycle distribution, decreasing growth of cultured cysts in vitro, and inhibiting hepatorenal cystogenesis in vivo in PCK rats and Pkd2WS25/- mice. The levels of IGF1 (but not VEGF) were reduced only in response to PAS. Expression of SSTR1 and SSTR2 (but not SSTR3 and SSTR5) was decreased in cystic cholangiocytes compared to control. Although both OCT and PAS increased the immunoreactivity of SSTR2, only PAS up-regulated SSTR1; neither drug affected cellular localization of SSTRs. Conclusion: PAS is more effective than OCT in reducing hepatorenal cystogenesis in rodent models; therefore, it might be more beneficial for the treatment of PKD and PLD. (HEPATOLOGY 2013)
Polycystic liver (PLD) and kidney (PKD) diseases are genetic disorders linked to disturbances in many intracellular signaling pathways and cell functions.1-3 One of the well-defined mechanisms involved in hepatorenal cystogenesis is increased accumulation of intracellular cyclic adenosine monophosphate (cAMP) that triggers cell hyperproliferation, cell cycle deregulation, and fluid secretion. Basal cAMP levels in cholangiocytes are maintained by the coordinated functioning of: (1) secretin receptors (activation of which by secretin increases cAMP); (2) somatostatin receptors ([SSTRs], activation of which by somatostatin inhibits cAMP); (3) adenylyl cyclases (crucial for cAMP production); and (4) phosphodiesterases (critical for cAMP degradation).1, 2
Activation of SSTRs induces multiple transduction pathways and mediates several cellular functions; however, inhibition of cell proliferation is one of the major effects.4, 5 Cholangiocytes express all five SSTRs (i.e., SSTR1 through 5).6, 7 Importantly, targeting of SSTRs with synthetic somatostatin analogs in patients with PLD and PKD has limited but unequivocal benefit by reducing cyst growth.3, 7-10
The natural SSTR ligand, somatostatin, is susceptible to proteolytic degradation and has a short half-life (∼3 minutes), limiting its clinical utility.5 Over the years, multiple stable somatostatin analogs have been developed. Octreotide (OCT; Sandostatin, SMS 201-95), a synthetic octapeptide with a half-life of 2 hours, was the first clinically introduced analog. We and others have tested the effects of OCT in preclinical and clinical trials in PLD and PKD.7-11 However, despite beneficial results (i.e., symptom relief and cyst reduction), changes in liver and kidney volumes in patients are moderate; thus, additional pharmacologic approaches are needed.
OCT binds with high affinity to SSTR2 and SSTR3, with moderate affinity to SSTR5, and has no affinity to SSTR1 and SSTR4.5, 12, 13 Because all five SSTRs coexist in cholangiocytes and renal epithelia,6, 7, 14 somatostatin analogs with higher binding affinity to a broader range of SSTRs might be more effective. Recently, the cyclohexapeptide pasireotide (PAS, SOM-230) has been evaluated experimentally and clinically for the treatment of different pathological conditions.12, 13 PAS has a high affinity to SSTR1, SSTR2, SSTR3, and SSTR5 and a half-life of 12 hours.12, 13, 15 Thus, we hypothesized that PAS should have more potent suppressive effects than OCT on cyst growth.
We used in vitro and in vivo experimental systems and models to compare the effects of OCT and PAS on cAMP levels, cell proliferation, cell cycle distribution, and hepatic cyst growth in vitro; and hepatorenal cystogenesis in two animal models of PLD and PKD, the PCK rat and Pkd2WS25/- mice. Expression of SSTRs in control and cystic cholangiocytes was assessed under basal conditions and after treatment. In addition, we examined concentrations of insulin-like growth factor 1 (IGF1) and vascular endothelial growth factor (VEGF) in response to OCT and PAS because these growth factors are linked to indirect inhibitory action of somatostatin analogs and are known to trigger hepatorenal cystogenesis by way of autocrine and paracrine mechanisms.15-19
We show that PAS has stronger suppressive effects on hepatorenal cystogenesis compared to OCT and thus might be more beneficial than OCT in patients with PLD and PKD.
Materials and Methods
Animals and Cell Cultures.
Rats and mice were maintained on a standard diet and water ad libitum. After anesthesia (pentobarbital; 50 mg/kg) liver and kidney were fixed and paraffin-embedded. Cholangiocytes were isolated from control and PCK rats as described20 and from liver transplant tissue of healthy human beings and patients with ADPKD (see Supporting Information for details). PAS and OCT were kindly provided by Novartis USA. The protocol was approved by the Mayo Institutional Animal Care and Use Committee (IACUC).
The treatment protocol is shown in Fig. 1. Rodents received PAS and OCT for 6 weeks. Drug doses were chosen based on our studies.7 Somatostatin analogs were dissolved in sterile water and administered by way of osmotic mini-pumps (model 2002, Alzet Osmotic Pumps, Cupertino, CA). Pumps were implanted subcutaneously on the animal back under anesthesia with 1.5% isoflurane (Baxter, Deerfield, IL). They were replaced every 2 weeks; at this time, OCT and PAS concentrations were adjusted to the animal weight. Cystic and fibrotic areas were analyzed as described in the Supporting Information (also for additional experimental procedures).
PAS Decreased Intracellular cAMP Levels to a Greater Extent than OCT.
Under basal conditions (no forskolin), levels of cAMP in PCK and ADPKD cholangiocytes were higher ∼5 and 4 times compared to respective controls (Fig. 2A,B). Forskolin increased cAMP production ∼2 times in rat control and PCK cholangiocytes and ∼3 times in human control and ADPKD cholangiocytes. Neither OCT or PAS affected cAMP accumulation in control rat and human cholangiocytes under basal conditions but suppressed it after forskolin stimulation. In contrast, in cystic PCK and ADPKD cholangiocytes, both somatostatin analogs, inhibited cAMP levels in the absence or presence of forskolin. Importantly, we observed more significant cAMP suppression by PAS than OCT (Fig. 2A,B).
OCT and PAS Affected the Cell Cycle.
In rat control cholangiocytes, OCT had no effect on the cell cycle distribution, whereas PAS increased cell number in S phase from 9.07 ± 0.59% to 10.93 ± 0.46% and decreased it in G2/M phase from 4.08 ± 1.82 to 1.06 ± 0.88% (Fig. 3A,B). In PCK cholangiocytes, OCT and PAS similarly affected the cell cycle profile by increasing the percentage of cells in S phase from 13.17 ± 1.48% to 16.27 ± 1.30% (OCT) and 17.99 ± 2.07% (PAS). In G2/M phase, the number of cells was decreased from 8.29 ± 1.72% to 3.41 ± 1.33 in response to OCT and to 1.77 ± 0.62% in response to PAS (Fig. 3A,B).
OCT had no effects on the cell cycle progression in human control cholangiocytes, whereas PAS increased the number of cells in G1 phase from 82.11 ± 0.54% to 85.50 ± 1.04% and decreased it in S phase from 8.88 ± 1.01% to 5.30 ± 0.89% (Fig. 3C,D). The number of ADPKD cholangiocytes during the cell cycle was: (1) elevated in G1 phase from 55.66 ± 1.31 to 71.03 ± 0.55 (OCT) and to 78.69 ± 1.06 (PAS); (2) decreased in S phase from 33.31 ± 1.45 to 19.91 ± 0.79 (OCT) and to 13.47 ± 1.35 (PAS); and (3) decreased in G2/M phase from 11.03 ± 0.65 to 9.07 ± 0.43 (OCT) and to 7.83 ± 0.34 (PAS) (Fig. 3C,D).
PAS Decreased Cell Proliferation More Effectively than OCT.
Cell proliferation in response to somatostatin analogs was examined by 3-(4,5-dimethyl-thiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and bromodeoxyuridine (BrdU) assays. MTS assay demonstrated that in response to OCT, proliferation of rat control and PCK cholangiocytes was decreased by 9.6% and 16.8%, respectively, and in response to PAS by 18.6% and 24.3%, respectively (Fig. 3E). In human control and ADPKD cholangiocytes, OCT inhibited the rates of proliferation by 12.9% and 18.4%, respectively, and PAS by 21.9% and 33.7%, respectively (Fig. 3E). By BrdU assay, OCT and PAS suppressed, respectively, proliferation of: (1) rat control cholangiocytes by 15.5% and 24.4%; (2) PCK cholangiocytes by 25.1% and 32.9%; (3) human control cholangiocytes by 12.5% and 19.8%; and (4) ADPKD cholangiocytes by 29.8% and 38.5% (Fig. 3F). Importantly, PAS repressed cell proliferation to a higher extent than OCT in rat and human control and cystic cholangiocytes (Fig. 3E,F).
PAS Inhibited Expansion of Hepatic Cysts in 3D Matrices More Extensively than OCT.
Under basal conditions, both control and PCK cysts expanded progressively over time (Fig. 4), although PCK structures grew to a greater extent. The circumferential area of control cysts enlarged by 92.07 ± 5.45% compared to a 228.50 ± 25.32% increase in PCK cultures. In response to OCT, the expansion of control and PCK cysts was decreased 1.6 and 2.3-fold, respectively; whereas PAS reduced enlargement of control and PCK cysts by 2.2- and 4.7-fold, respectively. No differences were observed between OCT- or PAS-treated control cysts; however, the suppressive effects of PAS on growth of PCK cystic structures were more noteworthy compared to OCT (Fig. 4).
PAS Reduced Hepatorenal Cystogenesis in Animal Models of PLD and PKD More Effectively than OCT.
Both somatostatin analogs were well tolerated by PCK rats and Pkd2WS25/- mice.
In PCK rats, OCT and PAS reduced, respectively: (1) liver weights by 9% and 16%; (2) kidney weights by 7% and 14%; (3) hepatic cystic areas by 24% and 36%; (4) hepatic fibrotic areas by 10% and 19%; (5) renal cystic areas by 22% and 30%; and (6) renal fibrotic areas by 10% and 19% (Supporting Table 1; Fig. 5). In Pkd2WS25/- mice, OCT and PAS treatment decreased, respectively: (1) liver weights by 17% and 22%; (2) kidney weights by 16% and 20%; (3) hepatic cystic areas by 22% and 34%; (4) hepatic fibrotic areas by 13% and 25%; (5) renal cystic areas by 19% and 30%; and (6) renal fibrotic areas by 18% and 25% (Supporting Table 2; Fig. 6). Moreover, PAS decreased hepatic and renal cystic and fibrotic areas in PCK rats (Supporting Table 1; Fig. 5B,D) and Pkd2WS25/- mice (Supporting Table 2; Fig. 6B,D) to a greater extent than OCT.
IGF1 Levels Were Reduced After PAS Treatment.
No changes in VEGF serum concentrations were observed in response to either OCT or PAS treatment in PCK rats. Serum levels of IGF1 were not affected by OCT, whereas PAS decreased it by 18% (P < 0.05) compared to control. Consistent with in vivo observation, suppressed secretion of IGF1 in the presence of PAS (but not OCT) was found in cultured rat control (by 10.8%; P < 0.03) and PCK (by 21.5%; P < 0.001) cholangiocytes, and human control (by 11.2%; P < 0.03) and ADPKD (by 15.7%; P < 0.01) cholangiocytes (Supporting Fig. 1).
SSTRs Are Differentially Expressed in Cystic Cholangiocytes.
Expression of SSTR1, SSTR2, SSTR3, and SSTR5 (i.e., targets of OCT and/or PAS) were detected in cholangiocytes of control and PCK rats, control and Pkd2WS25/- mice, healthy human beings, and patients with PLD by confocal microscopy (Fig. 7A,B) and western blotting (Fig. 7C). Levels of SSTR1 and SSTR2 were decreased in cystic cholangiocytes, whereas expression of SSTR3 and SSTR5 did not change compared to control.
OCT and PAS Altered the Expression of SSTRs.
Exposure to somatostatin analogs similarly affected expression of SSTRs in PCK rats and Pkd2WS25/- mice (Fig. 8A). OCT treatment increased levels of one of the SSTRs, SSTR2, whereas PAS treatment increased immunoreactivity of two SSTRs, SSTR1 and SSTR2, compared to nontreated cholangiocytes. This observation was also confirmed in vitro in cultured PCK cholangiocytes (Fig. 8B). In control PCK rats and Pkd2WS25/- mice, all four SSTRs mainly resided in the cytoplasm of cystic cholangiocytes and their distribution was not changed in response to either somatostatin analogs (Fig. 8A).
The major findings described here relate to the relative potencies of OCT and PAS in hepatic and renal cystogenesis. Using in vitro and in vivo experimental models representing two forms of polycystic liver diseases, ARPKD and ADPKD, we show that PAS is more effective than OCT in: (1) reducing cAMP levels; (2) decreasing cell proliferation; (3) affecting cell cycle distribution; (4) suppressing growth of cultured hepatic cysts; and (5) inhibiting hepatorenal cystic disease in PCK rats and Pkd2WS25/- mice. We also found that: (1) expression of SSTR1 and SSTR2, but not SSTR3 and SSTR5, is decreased in cystic cholangiocytes of animal models and patients with PKD and PLD compared to their respective controls; (2) OCT and PAS treatment increases immunoreactivity of SSTR2 in cholangiocytes of PCK rats and Pkd2WS25/- mice, whereas SSTR1 is up-regulated only by PAS; (3) localization of SSTRs is not affected by treatment with either analog; and (4) the IGF1 concentration is decreased only in response to PAS, whereas VEGF is not affected by either somatostatin analog.
The effects of OCT and PAS on hepatorenal cystic disease are executed by way of activation of multiple SSTRs. PAS has high affinity to four SSTRs, with a median inhibitory concentration (IC50) of 9.3 nM (SSTR1), 1.0 nM (SSTR2), 1.5 nM (SSTR3), and 0.16 nM (SSTR5).12, 13, 21 OCT binds to three SSTRs displaying IC50 of 2.0 nM (SSTR2), 187 nM (SSTR3), and 22 nM (SSTR5).21 PAS is more stable (i.e., 12-hour half-life) than OCT (i.e., 70-113 minutes).12 The rationale for the superior efficacy of PAS is that it acts not only on SSTR2 but also on other SSTRs.13, 22, 23 Because all five SSTRs are expressed in cholangiocytes and renal epithelial cells,6, 7, 14 we performed this comparative study and, indeed, our results suggest that PAS should be more beneficial than OCT for the treatment of polycystic disease in humans.
Our data showing that OCT and PAS inhibit cAMP, decrease cholangiocyte proliferation, and affect the cell cycle machinery support previous observations by us and others.7, 24-26 Reduction of cAMP levels is triggered by activation of any of the SSTRs.4, 27 In contrast, the effects of somatostatin analogs on the cell proliferation and cell cycle machinery occur predominantly by way of SSTR2 and SSTR5 and, in some cases, SSTR1.13, 28, 29 Activation of SSTR3 is also known to reduce proliferation and/or induce apoptosis.4 Indeed, we found that OCT and PAS inhibited cAMP and cell proliferation in rat and human cystic cholangiocytes in vitro and decreased mitotic indices and increased apoptotic indices in rodent models of PLD and PKD. Moreover, the effects of PAS were consistently more potent than OCT. In line with our data, PAS has been shown by others to decrease cell proliferation and cAMP in several different cell lines to a greater extent than OCT.17, 21, 24-26 We speculate that more potent PAS effects are likely related to the following. First, we observed the reduced expression of SSTR1 and SSTR2 in cystic cholangiocytes, whereas levels of SSTR3 and SSTR5 were not affected. Second, SSTR2, SSTR3, and SSTR5 are targets of OCT and PAS, whereas SSTR1 is the target of PAS only. Third, the binding affinity of PAS to SSTR3 and SSTR5 is 5-fold and 39-fold, respectively, higher compared with OCT.17
OCT and PAS modulate their action both by way of direct (i.e., cell proliferation, apoptosis, and cell cycle regulation) and indirect effects. Indirect effects occur, in particular, through inhibition of secretion of IGF1 and VEGF.13, 15 Both growth factors are overexpressed in cystic cholangiocytes and have been implicated in hepatorenal cystogenesis influencing cyst growth by both autocrine and paracrine pathways.3, 16, 18, 19 In the present study, the VEGF concentrations were not affected by either drug. OCT also had no effect on IGF1 concentration, whereas PAS reduced it. This result is consistent with previous data and suggests that the observed greater action of PAS on hepatic cyst growth might also be linked to indirect action of PAS by inhibiting IGF1.12, 15, 17
We and others have previously reported that all five SSTRs are localized to rat and human cholangiocytes.6, 7 Our data showing the decreased levels of SSTR1 and SSTR2 (but not SSTR3 and SSTR5) in cystic cholangiocytes are novel. To this end, the most plausible explanation for the moderate therapeutic success seen in patients with PLD and PKD is that current somatostatin analogs target mainly SSTR2, the expression of which appears to be decreased in hepatic cysts.
Native somatostatin and its synthetic analogs have the ability to regulate the expression levels of SSTRs by as yet not well understood mechanisms.21, 30 It has been suggested that up-regulation of SSTRs results in a longer lasting functional responses to agonist exposure.21 We showed that immunoreactivity of SSTR2 (in response to OCT and PAS) and SSTR1 (in response to PAS) is increased in cystic cholangiocytes. These changes in drug-induced receptor expression likely also contribute to the stronger suppressive effects of PAS because it binds to both SSTR1 and SSTR2. Finally, cytoplasmic localization of SSTRs which we detected in cystic cholangiocytes has also been observed in other tissues31 and reflects the functional state of somatostatin receptors due to internalization after agonist exposure.21
In conclusion, the more potent effects of PAS compared to OCT on hepatorenal cystogenesis observed in this study are likely related to a combination of features of both the drug and the cystic cell phenotype including: (1) a broader range of SSTRs targeted by PAS; (2) a higher affinity of PAS to SSTR3 and SSTR5 (expression of which in cystic cholangiocytes is unchanged compared to control); and (3) the extended half-life of PAS. Our data suggest that PAS may be more effective for the treatment of PLD and PKD than OCT. A clinical trial (NCT01670110) to assess the effectiveness of PAS in hepatorenal cystogenesis in patients with ADPKD and ADPLD is now under way at our institution.
Additional Supporting Information may be found in the online version of this article.
|HEP_26140_sm_SuppFig1.tif||341K||Supporting Information Figure 1.|
|HEP_26140_sm_SuppTables.doc||58K||Supporting Information Tables|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.